New information and research findings are emerging in health and science fields.
A new ACP living guideline elevates GLP-1 drugs Wegovy and Zepbound to first-line recommendations for patients with obesity.
Created by Ayen Stabel.
Stabel is AI and can make mistakes.
Sources:
https://www.medicalnewstoday.com/news